Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
Lisa Zimmer(The University of Sydney), Jochen Utikal(German Cancer Research Center), Patrick Terheyden(University Hospital Schleswig-Holstein), Christine Windemuth-Kieselbach(Statistisches Bundesamt), Bastian Schilling(Goethe University Frankfurt), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Uwe M. Martens(Memorial Sloan Kettering Cancer Center), Sebastian Haferkamp(University Hospital Regensburg), Alexander Rösch(Essen University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Axel Hauschild(University Hospital Schleswig-Holstein), Elisabeth Livingstone(German Cancer Research Center), Silvia Körner(Heidelberg University), Thomas Eigentler(University Children's Hospital Tübingen), Carola Berking(Universitätsklinikum Erlangen), Beate Conrad(Fachklinik Hornheide), Jürgen C. Becker(Düsseldorf University Hospital), Jessica C. Hassel(German Cancer Research Center), Michael Fluck(Fachklinik Hornheide), Carmen Loquai(Johannes Gutenberg University Mainz), Felix Kieker(Charité - Universitätsmedizin Berlin), Leonora Schwarz(Statistisches Bundesamt), Christian Menzer(Heidelberg University), Sabine Sell, Rudolf Stadler(University Hospitals of the Ruhr-University of Bochum), Jan‐Christoph Simon(Leipzig University), Claus Garbe(University of Tübingen)
Cited by 242
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k